- JBI-778, a brain penetrant PRMT5 inhibitor demonstrated
significant tumor growth inhibition in glioblastoma in addition to
its activity against a number of other cancers
- JBI-1527, a potent, selective oral inhibitor of PD-L1
exhibited T-cell restoration and immune-mediated tumor growth
suppression
- Data support the further development of PRMT5 inhibitor
JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet
need in oncology
BEDMINSTER, N.J., April 10, 2021 /PRNewswire/ -- Jubilant
Therapeutics Inc., a biopharmaceutical company advancing oral,
small molecule modulators to address unmet medical needs in
oncology and autoimmune diseases, today announced that preclinical
data from two programs evaluating the company's PRMT5 inhibitor and
PD-L1 inhibitor as anti-cancer agents, will be presented today in a
poster session at the American Association for Cancer Research
(AACR) 2021 Annual Meeting taking place virtually from April 10-15, 2021.
"We are excited to announce these important data from our PRMT5
and our PD-L1 programs that show efficacy and tolerability in
preclinical models," said Syed
Kazmi, President and Chief Executive Officer of Jubilant
Therapeutics Inc. "Our oral PRMT5 inhibitor has good plasma and
sustained brain exposure which results in strong target inhibition,
tumor growth delay and survival advantage in both xenografts and
orthotopic brain models. Our oral anti-PDL1 immunotherapeutics,
with a shorter half-life, are an attractive alternative to current
intravenous antibody therapies especially in the maintenance
settings with potential to limit immune-mediated toxicities and
side effects via innovative dosing approaches, while maintaining
the class-based wide anti-tumor efficacy. We look forward to
continuing our work on these programs as we see great potential for
treating multiple cancers."
A link to the e-posters, listed below, is available through the
AACR website.
Title: Novel, small molecule PRMT5 inhibitors for
treatment of cancer
Poster Number: 1128
Date and Time: April 10, 2021
at 8:30 a.m. Eastern Daylight Time
(EDT)
Session Title: Epigenetic Targets
Presenter: Dhanalakshmi Sivanandhan, et al.
Title: Novel, small molecule inhibitors of PD-L1/PD-1
interaction
Poster Number: 1630
Date and Time: April 10, 2021
at 8:30 a.m. Eastern Daylight Time
(EDT)
Session Title: Immune Checkpoints
Presenter: Dhanalakshmi Sivanandhan, et al.
PRMT5 over-expression, shown in several cancers including
lymphoid, lung, breast, glioblastoma, gastric etc., is thought to
be an important factor in its tumorigenicity due to its repressive
function on tumor suppressor gene expression. Key highlights from
an evaluation which examined the tumor growth inhibition of PRMT5
inhibitor JBI-778 in multiple cancer cell lines as well as
glioblastoma, include the following:
- JBI-778 is a potent PRMT5 inhibitor that is selective against
other PRMTs;
- JBI-778 shows potent anti-proliferative activity against a
number of cancers;
- This oral small molecule demonstrated anti-tumor efficacy in a
Mantle Cell lymphoma model with an ED50 of < 10 mg/Kg and a
complete tumor growth inhibition (97%) at a dose of 50mg/kg;
and
- JBI-778 exhibited sustained brain exposure and significant
tumor growth inhibition in an orthotopic glioblastoma model,
translating into substantial survival advantage.
JBI-778 is currently being evaluated for the treatment of
multiple cancers and IND-enabling studies have commenced.
PD-L1 expression is an immune evasion mechanism exploited by
many cancers, such as melanoma, non-small cell lung cancer and
breast cancer, which permits cancer progression and metastasis. Key
highlights from the PD-L1/PD-1 study which examined the ability of
JBI-1527 to inhibit PD-L1 and restore T-cell proliferation and
function, include the following:
- JBI-1527 is a potent, selective inhibitor of PD-L1 which
induces dimerization of the protein thereby alleviating
PD-L1-induced suppression of T cell activation;
- The inhibitor shows similar modulation of cytokines as
Pembrolizumab in BioMAP assay and competes with anti-PD-L1 blocking
antibody suggesting similar binding site on PD-L1; and
- In CT-26 and MC38-hPD-L1 syngeneic models, the small molecule
showed strong tumor growth inhibition comparable to anti-PD-L1
mAb/Atezolizumab, and was well tolerated.
Studies to further assess JBI-1527 and additional compounds are
underway.
Jubilant Therapeutics Inc. is developing a pipeline of novel,
differentiated therapeutic assets; for partnership opportunity
inquiries please contact bd@jubilanttx.com.
About Jubilant Therapeutics
Jubilant Therapeutics Inc. is a patient-centric
biopharmaceutical company advancing potent and selective small
molecule modulators to address unmet medical needs in oncology and
autoimmune diseases. Its advanced discovery engine integrates
structure-based design and computational algorithms to discover and
develop novel, precision therapeutics against both first-in-class
and validated but intractable targets in genetically-defined
patient populations. The Company's entrepreneurial-minded
leadership and scientific teams strive for speed and efficiency by
employing a business model that leverages the proven and
synergistic capabilities of Jubilant Pharmova Limited's value chain
and shared services. Jubilant Therapeutics is headquartered in the
U.S. and guided by globally renowned key opinion leaders and
scientific advisory board members. For more information,
please visit www.jubilanttx.com or follow us on Twitter @JubilantTx
and LinkedIn.
Logo -
https://mma.prnewswire.com/media/1064788/Jubilant_Therapeutics_Logo.jpg